However, combining IGF-1R inhibitors with BET inhibitors, or mTOR inhibitors, presents a synergistic effect on the inhibition of survival and tumor growth of ES cells both in vivo and in vitro (Loganathan et al., 2019). The gene discussed is IGF1R; the disease is neoplasm.